GENF
NEUTRALGenflow Completes Dosing Phase of Canine Gene Therapy Trial
The biotechnology company has successfully completed the dosing phase of its canine gene therapy trial, with no adverse events reported during administration.
Genflow Biosciences
1.8000GBX
-1.37%
Market Cap
8.88M
Volume
687.92k
14% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
2.31
Day Range
1.7120p - 1.9000p
52 Week Range
0.5500p1.8000p2.7000p
1.8000p
Upcoming Events
GENF
NEUTRALGenflow to Attend Healthcare Conference
The biotechnology company will attend an influential healthcare investment conference, providing an opportunity to engage with potential partners and investors.
GENF
NEUTRALGenflow Biosciences Director Increases Stake
The biotechnology company has announced a director has increased their shareholding in the business.
GENF
NEUTRALGenflow Biosciences Publishes Second European Patent Application
The biotechnology company has published its second European patent application, marking progress in expanding its intellectual property portfolio.
GENF
NEUTRALGenflow Biosciences Receives European Patent Office Recognition for SIRT6 Variant Patent
The biotechnology company has received recognition from the European Patent Office for the patentability of its SIRT6 variant patent, a key step in securing intellectual property protection for its longevity gene therapy platform.
GENF
NEUTRALGenflow Biosciences Provides Update on Animal Health Program
The biotechnology company provides an update on the progress of its SIRT6 gene therapy for age-related decline in elderly dogs, reporting successful second administration with no adverse effects.
GENF
NEUTRALGenflow Biosciences Provides Update on Equity Issue
The biotechnology company provides an update on an equity issue, including the termination of an initial transaction and the subscription of new ordinary shares.
GENF
BADGenflow Biosciences Raises £340,000 in Discounted Placing
The biotechnology company has raised £340,000 through a discounted share placing, signaling potential financial difficulties.
GENF
BADGenflow Biosciences Raises £340,000 Through Discounted Equity Placement
The biotechnology company has raised £340,000 through a discounted equity placement, signaling potential financial difficulties and low investor confidence.
GENF
BADGenflow Biosciences Reports Widening Losses in Half-Year Results
The pre-revenue biotech firm reported widening losses and increased cash burn in its half-year results, despite progress in clinical programs. Material uncertainty around going concern raises questions about future funding needs.